Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 26

1.

Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine production.

Montomoli E, Khadang B, Piccirella S, Trombetta C, Mennitto E, Manini I, Stanzani V, Lapini G.

Expert Rev Vaccines. 2012 May;11(5):587-94. doi: 10.1586/erv.12.24. Review.

PMID:
22827244
2.

Continuous cell lines as a production system for influenza vaccines.

Genzel Y, Reichl U.

Expert Rev Vaccines. 2009 Dec;8(12):1681-92. doi: 10.1586/erv.09.128. Review.

PMID:
19943763
3.

Developing cell culture-derived pandemic vaccines.

Barrett PN, Portsmouth D, Ehrlich HJ.

Curr Opin Mol Ther. 2010 Feb;12(1):21-30. Review.

PMID:
20140813
4.

Preflucel®: a Vero-cell culture-derived trivalent influenza vaccine.

Chan CY, Tambyah PA.

Expert Rev Vaccines. 2012 Jul;11(7):759-73. doi: 10.1586/erv.12.55. Review.

PMID:
22913252
5.

Egg-independent vaccine strategies for highly pathogenic H5N1 influenza viruses.

Pandey A, Singh N, Sambhara S, Mittal SK.

Hum Vaccin. 2010 Feb;6(2):178-88. Epub 2010 Feb 24. Review.

6.

Aflunov(®): a prepandemic influenza vaccine.

Gasparini R, Amicizia D, Lai PL, Panatto D.

Expert Rev Vaccines. 2012 Feb;11(2):145-57. doi: 10.1586/erv.11.170. Review.

PMID:
22309663
7.

Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines.

Barrett PN, Mundt W, Kistner O, Howard MK.

Expert Rev Vaccines. 2009 May;8(5):607-18. doi: 10.1586/erv.09.19. Review.

PMID:
19397417
8.

Strategies for developing vaccines against H5N1 influenza A viruses.

Horimoto T, Kawaoka Y.

Trends Mol Med. 2006 Nov;12(11):506-14. Epub 2006 Sep 29. Review.

PMID:
17011235
9.

Vaccines against seasonal and pandemic influenza and the implications of changes in substrates for virus production.

Minor PD.

Clin Infect Dis. 2010 Feb 15;50(4):560-5. doi: 10.1086/650171. Review.

PMID:
20085485
10.

[Safety of cell culture-based influenza vaccines].

Schmitt HJ, Gregersen JP, Trusheim H, Bröker M.

Med Monatsschr Pharm. 2010 Jan;33(1):4-10. Review. German.

PMID:
20131669
11.

Vaccines in development against avian influenza.

Cox MM.

Minerva Med. 2007 Apr;98(2):145-53. Review.

PMID:
17519856
12.

[Influenza vaccine].

Horimoto T, Murakami S, Kawaoka Y.

Nihon Rinsho. 2008 Oct;66(10):2013-8. Review. Japanese.

PMID:
18939506
13.

[Tetravaccine--new fundamental approach to prevention of influenza pandemic].

Onishchenko GG, Zverev VV, Katlinskiĭ AV, Semchenko AV, Korovkin SA, Mel'nikov SIa, Mironov AN.

Zh Mikrobiol Epidemiol Immunobiol. 2007 Jul-Aug;(4):15-9. Review. Russian.

PMID:
17882832
14.

Influenza vaccines: the good, the bad, and the eggs.

Schultz-Cherry S, Jones JC.

Adv Virus Res. 2010;77:63-84. doi: 10.1016/B978-0-12-385034-8.00003-X. Review.

PMID:
20951870
15.

Lessons from pandemic influenza A(H1N1): the research-based vaccine industry's perspective.

Abelin A, Colegate T, Gardner S, Hehme N, Palache A.

Vaccine. 2011 Feb 1;29(6):1135-8. doi: 10.1016/j.vaccine.2010.11.042. Epub 2010 Nov 27. Review.

16.

Pre-pandemic and pandemic influenza vaccines.

Rockman S, Brown L.

Hum Vaccin. 2010 Oct;6(10):792-801. Epub 2010 Oct 1. Review.

PMID:
20935469
18.
19.

[Influenza, an existing public health problem].

García-García J, Ramos C.

Salud Publica Mex. 2006 May-Jun;48(3):244-67. Review. Spanish.

20.

Vero cell culture-derived pandemic influenza vaccines: preclinical and clinical development.

Barrett PN, Portsmouth D, Ehrlich HJ.

Expert Rev Vaccines. 2013 Apr;12(4):395-413. doi: 10.1586/erv.13.21. Review.

PMID:
23560920

Supplemental Content

Support Center